Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Amgen (0R0T) Share Price & Analysis

4 Followers

0R0T Stock Chart & Stats

$465.61-$3.57(-0.76%)
At close: 4:30 PM GMT
$400$450Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$461.10 - $475.52
52-Week Range
$312.20 - $497.50
Previous Close
$469.18
Volume
N/A
Average Volume (3M)
2,482
Market Cap
$251.89B
Enterprise Value
$270.96B
Total Cash (Recent Filing)
$13.19B
Total Debt (Recent Filing)
$54.01B
Price to Earnings (P/E)
26.8
Beta
0.66
Next Earnings
Feb 09, 2027 (Est.)
EPS Estimate
5.64
Next Dividend Ex-Date
N/A
Dividend Yield
2.13%

Bulls Say, Bears Say

Bulls Say

Broad Portfolio Growth

Growth is broad rather than dependent on one product, with multiple therapies delivering double-digit gains and key drivers representing most product sales. This diversification supports more durable revenue expansion, improves commercial resilience, and gives Amgen a stronger base for continued investment.

Late-stage Pipeline Strength

Positive late-stage results across oncology, respiratory disease and Sjogren’s disease strengthen the pipeline’s potential to add future growth platforms. Multiple programs reduce reliance on existing products and support portfolio renewal as therapeutic needs and competitive conditions evolve.

Strong Profitability And Cash Generation

High margins and substantial operating and free cash flow provide internal funding for research, manufacturing capacity, acquisitions and shareholder returns. This cash-generative model gives Amgen flexibility to advance its pipeline while supporting ongoing commercial and operational investment.

Bears Say

Heavy Financial Leverage

Heavy leverage leaves Amgen more exposed if earnings weaken, because interest obligations and refinancing needs can absorb cash that might otherwise support innovation or shareholder returns. The relatively small equity base also amplifies financial risk when operating performance becomes less consistent.

Uneven Cash-flow Coverage

Although absolute cash generation is strong, declining free cash flow and inconsistent coverage indicate that conversion has not been uniformly dependable. Continued volatility could constrain debt reduction, investment capacity or capital returns if operating conditions become less favorable.

Reimbursement And Adoption Barriers

Reimbursement pressure outside the U.S. could limit access and slow the commercial ramp for MariTide, while treatment-management complexity may delay broader use of T-cell engagers. These barriers could reduce the pace at which pipeline opportunities translate into durable sales.

Amgen News

0R0T FAQ

What was Amgen’s price range in the past 12 months?
Amgen lowest share price was $312.20 and its highest was $497.50 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $251.89B.
When is Amgen’s upcoming earnings report date?
Amgen’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 86 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Nov 03, 2026. The company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.786 by $0.664.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Overvalued.
Does Amgen pay dividends?
Amgen does not currently pay dividends.
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 5.64.
How many shares outstanding does Amgen have?
Amgen has 540,911,500 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $6.45 in its last earnings report, beating expectations of $5.786. Following the earnings report the stock price went up 3.574%.
Which hedge fund is a major shareholder of Amgen?
Hedge funds hold Amgen shares: the largest hedge-fund position in Amgen is 1,140,035,348 shares, and hedge funds decreased their holdings by 2.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology